No items found.
Olympia Pharmaceuticals is a 503B outsourcing facility based in Orlando, Florida, founded in 2014. They supply compounded medications to pharmacies and clinics across 48 states. Like other large compounding facilities, they have been significantly impacted by FDA decisions ending the semaglutide and tirzepatide shortage declarations. Their pivot to liraglutide and other products represents a major strategic shift. Consumer feedback is extremely limited and predominantly negative, with a 1.0 out of 5 rating on ComplaintsBoard and multiple BBB complaints.
Olympia has demonstrated adaptability by pivoting quickly to liraglutide compounding after the FDA shortage declarations. Their 503B facility is licensed in 48 states, providing broad geographic reach. They recently expanded with a new facility (Wesley Pharmaceuticals) to increase production capacity. Their product catalog extends beyond GLP-1s to include NAD+, amino acids, vein care products, and sexual health medications, providing diversification for their provider partners.
The concerns with Olympia are significant. FDA 483 inspection findings from May 2024 documented quality control issues similar to those found at other large compounders. BBB complaints describe problems with billing, product quality, medications arriving without proper cold chain storage, and inaccurate information about expiration dates. One complaint even alleged fraudulent charges appearing after providing payment information. The very small review sample (8 reviews) with overwhelmingly negative sentiment suggests systemic customer experience issues rather than isolated incidents.
Olympia Pharmaceuticals is primarily relevant as a behind-the-scenes supplier rather than a consumer-facing brand. If your healthcare provider or pharmacy sources from Olympia, the regulatory findings and consumer complaints are worth noting. Their pivot to liraglutide shows business agility, but the quality concerns and very poor consumer feedback warrant careful consideration. Patients should ask their providers about pharmacy sourcing and quality assurance practices.
No. Olympia Pharmaceuticals is a 503B outsourcing facility, not a telehealth provider or direct-to-consumer service. They manufacture and supply compounded medications in bulk to pharmacies, clinics, and healthcare providers. Patients access their products through prescribing providers who partner with Olympia.
Following FDA decisions ending the semaglutide and tirzepatide shortage declarations, Olympia has pivoted primarily to compounding liraglutide, which remains on the FDA shortage list. They also offer weight management kits, amino acid formulations, and sermorelin as part of their product catalog.
The FDA declared that the shortages of semaglutide and tirzepatide had been resolved, which means compounding pharmacies can no longer legally produce compounded versions of these medications under the shortage exemption. Olympia has transitioned to liraglutide and other legally permissible alternatives.
Yes. Olympia Pharmaceuticals received FDA 483 inspection findings in May 2024, similar to other large compounding facilities. These findings documented concerns with fill weight discrepancies, quality control procedures, and reporting requirements. These findings are part of increased FDA scrutiny across the compounding industry.
Patients cannot purchase directly from Olympia Pharmaceuticals. Their products are distributed through licensed pharmacies and healthcare providers who maintain accounts with Olympia. If your provider or pharmacy uses Olympia as a supplier, you may receive their compounded medications as part of your treatment plan.